Cargando…
Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
BACKGROUND AND OBJECTIVES: Antibodies to CD20 efficiently reduce new relapses in multiple sclerosis (MS), and ocrelizumab has been shown to be effective also in primary progressive MS. Although anti-CD20 treatments efficiently deplete B cells in blood, some B cells and CD20(−) plasma cells persist i...
Autores principales: | Ho, Samantha, Oswald, Eva, Wong, Hoi Kiu, Vural, Atay, Yilmaz, Vuslat, Tüzün, Erdem, Türkoğlu, Recai, Straub, Tobias, Meinl, Ingrid, Thaler, Franziska, Kümpfel, Tania, Meinl, Edgar, Mader, Simone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880874/ https://www.ncbi.nlm.nih.gov/pubmed/36702538 http://dx.doi.org/10.1212/NXI.0000000000200083 |
Ejemplares similares
-
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022) -
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts
por: Schlüter, Miriam, et al.
Publicado: (2021) -
Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
por: Karaaslan, Zerrin, et al.
Publicado: (2023) -
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance
por: Vural, Atay, et al.
Publicado: (2018) -
Identification of circulating MOG-specific B cells in patients with MOG antibodies
por: Winklmeier, Stephan, et al.
Publicado: (2019)